BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 25006841)

  • 1. [Pulmonary neuroendocrine neoplasms].
    Sayeg Y; Sayeg M; Baum RP; Kulkarni HR; Presselt N; Mäder I; Kunze A; Sänger J; Hörsch D; Bonnet R
    Pneumologie; 2014 Jul; 68(7):456-77. PubMed ID: 25006841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bronchopulmonary neuroendocrine tumors.
    Gustafsson BI; Kidd M; Chan A; Malfertheiner MV; Modlin IM
    Cancer; 2008 Jul; 113(1):5-21. PubMed ID: 18473355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pulmonary neuroendocrine tumors in the new WHO 2015 classification: Start of breaking new grounds?].
    Schnabel PA; Junker K
    Pathologe; 2015 May; 36(3):283-92. PubMed ID: 25956813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pulmonary neuroendocrine tumors. The spectrum of histologic subtypes and current concept on diagnosis and treatment].
    Langfort R; Rudziński P; Burakowska B
    Pneumonol Alergol Pol; 2010; 78(1):33-46. PubMed ID: 20162517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteristics of 252 patients with bronchopulmonary neuroendocrine tumours treated at the Copenhagen NET Centre of Excellence.
    Grøndahl V; Binderup T; Langer SW; Petersen RH; Nielsen K; Kjaer A; Federspiel B; Knigge U
    Lung Cancer; 2019 Jun; 132():141-149. PubMed ID: 31097087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. hASH1 is a specific immunohistochemical marker for lung neuroendocrine tumors.
    Ye B; Cappel J; Findeis-Hosey J; McMahon L; Yang Q; Xiao GQ; Xu H; Li F
    Hum Pathol; 2016 Feb; 48():142-7. PubMed ID: 26596584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnosis and treatment of neuroendocrine lung tumors.
    Sánchez de Cos Escuín J
    Arch Bronconeumol; 2014 Sep; 50(9):392-6. PubMed ID: 24685201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroendocrine neoplasms of the lung: a prognostic spectrum.
    Asamura H; Kameya T; Matsuno Y; Noguchi M; Tada H; Ishikawa Y; Yokose T; Jiang SX; Inoue T; Nakagawa K; Tajima K; Nagai K
    J Clin Oncol; 2006 Jan; 24(1):70-6. PubMed ID: 16382115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular markers help characterize neuroendocrine lung tumors.
    Rusch VW; Klimstra DS; Venkatraman ES
    Ann Thorac Surg; 1996 Sep; 62(3):798-809; discussion 809-10. PubMed ID: 8784011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pulmonary atypical carcinoid: predictors of survival in 106 cases.
    Beasley MB; Thunnissen FB; Brambilla E; Hasleton P; Steele R; Hammar SP; Colby TV; Sheppard M; Shimosato Y; Koss MN; Falk R; Travis WD
    Hum Pathol; 2000 Oct; 31(10):1255-65. PubMed ID: 11070119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pulmonary neuroendocrine tumors: study of 90 cases focusing on clinicopathological characteristics, immunophenotype, preoperative biopsy, and frozen section diagnoses.
    Yeh YC; Chou TY
    J Surg Oncol; 2014 Mar; 109(3):280-6. PubMed ID: 24301337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic and diagnostic value of epithelial to mesenchymal transition markers in pulmonary neuroendocrine tumors.
    Galván JA; Astudillo A; Vallina A; Crespo G; Folgueras MV; González MV
    BMC Cancer; 2014 Nov; 14():855. PubMed ID: 25413006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ERCC1 and Ki67 in small cell lung carcinoma and other neuroendocrine tumors of the lung: distribution and impact on survival.
    Skov BG; Holm B; Erreboe A; Skov T; Mellemgaard A
    J Thorac Oncol; 2010 Apr; 5(4):453-9. PubMed ID: 20104194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of p53, K-ras-2, and C-raf-1 in pulmonary neuroendocrine tumors. Correlation with histological subtype and clinical outcome.
    Przygodzki RM; Finkelstein SD; Langer JC; Swalsky PA; Fishback N; Bakker A; Guinee DG; Koss M; Travis WD
    Am J Pathol; 1996 May; 148(5):1531-41. PubMed ID: 8623922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in neuroendocrine lung tumors.
    Travis WD
    Ann Oncol; 2010 Oct; 21 Suppl 7():vii65-71. PubMed ID: 20943645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alteration of the E-cadherin/beta-catenin cell adhesion system is common in pulmonary neuroendocrine tumors and is an independent predictor of lymph node metastasis in atypical carcinoids.
    Pelosi G; Scarpa A; Puppa G; Veronesi G; Spaggiari L; Pasini F; Maisonneuve P; Iannucci A; Arrigoni G; Viale G
    Cancer; 2005 Mar; 103(6):1154-64. PubMed ID: 15712207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Symptoms and diagnostics of lung neuroendocrine tumors].
    Tamási L; Müller V
    Orv Hetil; 2011 Mar; 152(10):366-70. PubMed ID: 21354952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular and cellular biology of neuroendocrine lung tumors: evidence for separate biological entities.
    Swarts DR; Ramaekers FC; Speel EJ
    Biochim Biophys Acta; 2012 Dec; 1826(2):255-71. PubMed ID: 22579738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid.
    Travis WD; Rush W; Flieder DB; Falk R; Fleming MV; Gal AA; Koss MN
    Am J Surg Pathol; 1998 Aug; 22(8):934-44. PubMed ID: 9706973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Surgical treatment of neuroendocrine tumors of the lung.
    Daddi N; Ferolla P; Urbani M; Semeraro A; Avenia N; Ribacchi R; Puma F; Daddi G
    Eur J Cardiothorac Surg; 2004 Oct; 26(4):813-7. PubMed ID: 15450578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.